Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
- Author
- PLOSKER, Greg L1
[1] Adis, Auckland, New Zealand - Source
Drugs (Basel). 2012, Vol 72, Num 17, pp 2289-2312, 24 p ; ref : 84 ref
- CODEN
- DRUGAY
- ISSN
- 0012-6667
- Scientific domain
- Pharmacology drugs
- Publisher
- Adis International, Auckland
- Publication country
- New Zealand
- Document type
- Article
- Language
- English
- Keyword (fr)
- Article synthèse Dapagliflozine Diabète de type 2 Essai clinique Homme Hypoglycémiant Revue bibliographique Traitement Inhibiteur du SGLT2 Endocrinopathie Maladie métabolique
- Keyword (en)
- Review Dapagliflozin Type 2 diabetes Clinical trial Human Hypoglycemic agent Bibliographic review Treatment SGLT2 inhibitor Endocrinopathy Metabolic diseases
- Keyword (es)
- Artículo síntesis Dapagliflozina Diabetes de tipo 2 Ensayo clínico Hombre Hipoglicemiante Revista bibliográfica Tratamiento Endocrinopatía Metabolismo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02O Hormones. Endocrine system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Discipline
- Endocrinopathies Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26763306
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"72\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2289\";s:8:\"\u0000*\u0000epage\";s:4:\"2312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PLOSKER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Greg L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"72\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2289\";s:8:\"\u0000*\u0000epage\";s:4:\"2312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PLOSKER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Greg L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"72\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2289\";s:8:\"\u0000*\u0000epage\";s:4:\"2312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PLOSKER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Greg L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"72\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2289\";s:8:\"\u0000*\u0000epage\";s:4:\"2312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PLOSKER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Greg L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"72\";s:8:\"\u0000*\u0000issue\";s:2:\"17\";s:8:\"\u0000*\u0000spage\";s:4:\"2289\";s:8:\"\u0000*\u0000epage\";s:4:\"2312\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PLOSKER\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Greg L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:62:\"Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
